331 related articles for article (PubMed ID: 36077453)
1. Genetic Variation among Pharmacogenes in the Sardinian Population.
Idda ML; Zoledziewska M; Urru SAM; McInnes G; Bilotta A; Nuvoli V; Lodde V; Orrù S; Schlessinger D; Cucca F; Floris M
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077453
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics at Scale: An Analysis of the UK Biobank.
McInnes G; Lavertu A; Sangkuhl K; Klein TE; Whirl-Carrillo M; Altman RB
Clin Pharmacol Ther; 2021 Jun; 109(6):1528-1537. PubMed ID: 33237584
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
[TBL] [Abstract][Full Text] [Related]
4. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
Pritchard D; Patel JN; Stephens LE; McLeod HL
Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
[TBL] [Abstract][Full Text] [Related]
5. Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank.
Li B; Sangkuhl K; Whaley R; Woon M; Keat K; Whirl-Carrillo M; Ritchie MD; Klein TE
Am J Hum Genet; 2023 Oct; 110(10):1628-1647. PubMed ID: 37757824
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.
Alshabeeb MA; Alyabsi M; Paras B
Saudi Pharm J; 2022 Aug; 30(8):1181-1192. PubMed ID: 36164570
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China.
Huang Q; Liao Y; Yu T; Lei W; Liang H; Wen J; Liu Q; Chen Y; Huang K; Jing L; Huang X; Liu Y; Yu X; Su K; Liu T; Yang L; Huang M
J Clin Lab Anal; 2023 Mar; 37(5):e24855. PubMed ID: 36916827
[TBL] [Abstract][Full Text] [Related]
8. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic landscape of Indian population using whole genomes.
Sahana S; Bhoyar RC; Sivadas A; Jain A; Imran M; Rophina M; Senthivel V; Kumar Diwakar M; Sharma D; Mishra A; Sivasubbu S; Scaria V
Clin Transl Sci; 2022 Apr; 15(4):866-877. PubMed ID: 35338580
[TBL] [Abstract][Full Text] [Related]
10. Population Diversity in Pharmacogenetics: A Latin American Perspective.
Suarez-Kurtz G; Parra EJ
Adv Pharmacol; 2018; 83():133-154. PubMed ID: 29801573
[TBL] [Abstract][Full Text] [Related]
11. Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E; Abouelhoda M; ElKalioby MM; Jabaan A; Alghithi N; Meyer BF; Monies D
PLoS One; 2022; 17(1):e0263137. PubMed ID: 35089958
[TBL] [Abstract][Full Text] [Related]
12. Fetal pharmacogenomics: A promising addition to complex neonatal care.
Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
[TBL] [Abstract][Full Text] [Related]
14. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
Nagy M; Attya M; Patrinos GP
Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490
[TBL] [Abstract][Full Text] [Related]
15. Population structure and pharmacogenomic risk stratification in the United States.
Nagar SD; Conley AB; Jordan IK
BMC Biol; 2020 Oct; 18(1):140. PubMed ID: 33050895
[TBL] [Abstract][Full Text] [Related]
16. Mining local exome and HLA data to characterize pharmacogenetic variants in Saudi Arabia.
Abouelhoda M; Almuqati N; Abogosh A; Alfraih F; Maddirevula S; Alkuraya FS
Hum Genet; 2024 Feb; 143(2):125-136. PubMed ID: 38159139
[TBL] [Abstract][Full Text] [Related]
17. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
Duarte JD; Dalton R; Elchynski AL; Smith DM; Cicali EJ; Lee JC; Duong BQ; Petry NJ; Aquilante CL; Beitelshees AL; Empey PE; Johnson JA; Obeng AO; Pasternak AL; Pratt VM; Ramsey LB; Tuteja S; Van Driest SL; Wiisanen K; Hicks JK; Cavallari LH;
Genet Med; 2021 Dec; 23(12):2335-2341. PubMed ID: 34282303
[TBL] [Abstract][Full Text] [Related]
18. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
[TBL] [Abstract][Full Text] [Related]
19. Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology.
Shriver SP; Adams D; McKelvey BA; McCune JS; Miles D; Pratt VM; Ashcraft K; McLeod HL; Williams H; Fleury ME
J Clin Oncol; 2024 Apr; 42(10):1181-1192. PubMed ID: 38386947
[TBL] [Abstract][Full Text] [Related]
20. Personalized medicine: Genetic risk prediction of drug response.
Zhang G; Nebert DW
Pharmacol Ther; 2017 Jul; 175():75-90. PubMed ID: 28213088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
